FDA gives accelerated approval to Eli Lilly's Alzheimer's drug donanemab

The U.S. Food and Drug Administration has granted accelerated approval to donanemab, an Eli Lilly monoclonal antibody for early-stage Alzheimer's disease. The decision gives patients and doctors another treatment option aimed at slowing the progression of the memory-robbing illness.

Reuters reported that the drug showed a meaningful reduction in cognitive decline in late-stage testing, with trial results suggesting it may slow symptoms by as much as 35% in people diagnosed early. The approval places donanemab among a new class of therapies designed to target the underlying disease process rather than only manage symptoms.

As with other accelerated approvals, the medication will remain under continued review as additional data are collected. Regulators typically use this pathway for treatments that address serious conditions and show signs of clinical benefit before the full evidence package is complete.

Alzheimer's affects millions of families in the United States and around the world, and new treatment options remain limited. For patients in the early stages of the disease, the FDA's decision could expand access to a therapy that may help delay some of the cognitive losses that define the illness.